(return to previous page)
Scott Johnson, who has been living with multiple sclerosis for over 35 years, is using his acumen as a business consultant and serial entrepreneur to reform a system for medical research and drug development that has failed to produce new patient treatments for millions living with chronic and debilitating diseases.
Featured in Fortune (September 2006) as a “lifesaving shakeup in the world of medical research”, Scott’s big idea has since delivered on that promise by (1) proving that basic science can be accelerated and (2) creating connections between academic scientists and those who commercially develop drugs. This will mean the faster development and delivery of patient treatments and cures.
The results of Scott’s Accelerated Research Collaboration™ model (ARC™) have been nothing short of extraordinary. Since its founding, the Myelin Repair Foundation-funded scientific collaboration has (1) identified over 100 novel potential targets; (2) developed many new research tools with broad application to all neurological disease research; (3) received seven U.S. patents and (4) published more than 120 scientific articles in peer-reviewed journals. To date, Scott raised $45 million from multiple sclerosis patients and Silicon Valley entrepreneurs toward this effort. Furthermore, more than 70 different disease-specific research organizations have expressed an interest in the model and how it might be used to leverage their own research investments.
Without pointing fingers, Scott explains how the current system for medical research and developing new drugs is failing to deliver patient treatments. His talks are inspirational for all patients and others with an interest in systemic change in complicated and archaic systems. His remarks are thoughtful and provocative.
He has spoken broadly on this topic at the National Cancer Instistute, the 12Gurus/NextGen Health conference, NASA, BIL/PIL, the Aspen Institute Health Forum and others. His ideas have been covered in the Wall Street Journal, Forbes, New York Times, Fast Company, The Atlantic, Newsweek, Businessweek, the San Francisco Chronicle and more. In 2006, he was named as one of Scientific American's top 50 worldwide for business, science and policy leadership. In addition, Scott was recognized as the Northern California Ernst & Young Entrepreneur Of The Year® in the Social Entrepreneurship category in 2010 and the award recipient of Research!America's 2012 Gordon and Llura Gund Leadership Award in 2012.
For more information contact:
Director of Communications
Myelin Repair Foundation
The Myelin Repair Foundation is a 501(c)(3), non-profit, tax-exempt charitable organization.
Photos by: Babuljak Photography
The content on this webpage is offered for informational purposes only. The information is not provided for the purpose of giving medical advice or recommending specific treatment options for any medical condition or health problem. You should never use the content of the webpage or any other information located on the website as a substitute for a thorough and complete discussion with your doctor about a medical condition or health problem you may have, and you should not rely on the materials in the websites when choosing a treatment plan or evaluating any other medical advice regarding any disease or medical condition. The Myelin Repair Foundation strongly urges you to consult one or more licensed physicians who are trained to diagnose and treat the symptoms of MS and other neurological diseases. The Myelin Repair Foundation makes no warranties whatsoever, express or implied, regarding the accuracy, completeness, timeliness, or usefulness of any information contained or referenced on the website. Health-related information and technology change frequently and therefore information contained in the website may be outdated, incomplete or incorrect. The Myelin Repair Foundation does not assume any risk whatsoever for your use of the information contained on the website and your use of the website and the materials contained herein is at your own risk.